Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Ensysce Biosciences, Inc. - Common Stock (NQ:ENSC)

0.5708 +0.0108 (+1.93%)
Delayed Quote Updated: 9:59 AM EDT, Oct 15, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Ensysce Biosciences, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
News headline image
Ensysce Biosciences Phase 2 Protocol for CY200 - A Neuroplastigen for the Treatment of CRPS - Submitted to the UK MHRA
~ Submission to the UK MHRA for review marks critical step towards initiating a Phase 2 Study with CY200 ~ 
From Ensysce Biosciences
Via ACCESS Newswire
News headline image
Ensysce Biosciences Advances CRPS Program at Painweek 2026, Contributes to FDA Hearing on Psychedelic Drug Regulation
From Ensysce Biosciences
Via ACCESS Newswire
News headline image
Ensysce Biosciences' Professor Richard Langford Selected to Speak at FDA Public Hearing on the Potential Future Therapeutic Use of Psychedelic Drugs
From Ensysce Biosciences
Via ACCESS Newswire
News headline image
Ensysce Biosciences Announces Upcoming Conference and Industry Event Participation
From Ensysce Biosciences
Via ACCESS Newswire
News headline image
Ensysce Biosciences Enrolls First Patient in Final Phase of PF614-MPAR-102 Clinical Study
From Ensysce Biosciences
Via ACCESS Newswire
News headline image
Ensysce Biosciences Completes Final Phase of PF614-MPAR-102 Clinical Study
From Ensysce Biosciences
Via ACCESS Newswire
News headline image
Ensysce Biosciences to Showcase "A New Era in Pain Therapeutics" at PAINWeek 2026 Symposium
From Ensysce Biosciences
Via ACCESS Newswire
News headline image
Ensysce Biosciences Reports Second Quarter 2026 Financial Results and Recent Business Highlights
From Ensysce Biosciences
Via ACCESS Newswire
News headline image
Ensysce Biosciences Announces Acquisition of Cy Biopharma and up to $77 Million Private Financing
From Ensysce Biosciences
Via ACCESS Newswire
News headline image
The Bull Lives Below $1: PRSO, ENSC, TNMG, QNME Stocks to Watch
Via AB Newswire
Topics Artificial Intelligence
News headline image
Ensysce Biosciences Awarded $5.3 Million Installment in NIDA Funding Completing Multi-Year $15 Million Federal Grant
From Ensysce Biosciences
Via ACCESS Newswire
News headline image
Ensysce Biosciences Reports First Quarter 2026 Financial Results
Via ACCESS Newswire
News headline image
Ensysce Biosciences Announces Expansion of Patent Protection for Groundbreaking MPAR(R) Overdose Protection Technology
Via ACCESS Newswire
News headline image
Ensysce Biosciences CEO Presents at Inaugural Clinical Pain Symposium in Amsterdam
Via ACCESS Newswire
News headline image
Ensysce Biosciences Secures IRB Approval of Final Phase of PF614-MPAR-102 Clinical Study
Via ACCESS Newswire
News headline image
Ensysce Biosciences Secures Second Financing From 2025 Agreement to Advance Breakthrough Pain Programs
Via ACCESS Newswire
News headline image
Ensysce Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results
Via ACCESS Newswire
News headline image
Ensysce Biosciences Initiates Live "Ask Me Anything" (AMA) Session Highlighting Growth and Future Plans
Via ACCESS Newswire
News headline image
Ensysce Biosciences Announces First Peer-Reviewed Clinical Publication Demonstrating Oral Overdose Protection with MPAR(R) Technology
Via ACCESS Newswire
News headline image
Rapid Dose Therapeutics (CSE: DOSE) (OTCQB: RDTCF) Advances QuickStrip™ Research Backed by NFL-Supported Clinical Evaluation – More Stocks Inside
Via AB Newswire
News headline image
Ensysce Biosciences Initiates Review of Strategic Alternatives to Enhance Shareholder Value
Via ACCESS Newswire
News headline image
Ensysce Biosciences Invited to Participate in Upcoming Scientific and Industry Events
Via ACCESS Newswire
News headline image
Ensysce Biosciences Expands Global Opioid Patent Portfolio
Via ACCESS Newswire
News headline image
Ensysce Biosciences Receives EU Patent Expanding its First-in-Class ADHD Therapy with Built-In Abuse and Overdose Protection
Via ACCESS Newswire
News headline image
Ensysce Biosciences Issues Annual Shareholder Letter
Via ACCESS Newswire
News headline image
Ensysce Biosciences Achieves Major Milestone with Initiation of Enrollment in Pivotal Phase 3 Trial of PF614, Its Next-Generation Opioid
Via ACCESS Newswire
News headline image
Ensysce Biosciences Announces Broader Patent Protection for Groundbreaking MPAR(R) Overdose Protection Technology
Via ACCESS Newswire
News headline image
Ensysce Biosciences Receives Positive FDA Feedback on PF614 Manufacturing Approach
Via ACCESS Newswire
News headline image
Ensysce Biosciences Secures $4 Million Financing, Unlocking Up to $20 Million in Total Financing to Advance Breakthrough Pain Programs
Via ACCESS Newswire
News headline image
Ensysce Biosciences Reports Third Quarter 2025 Financial Results
Via ACCESS Newswire
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.